ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
14.83
+0.21 (1.44%)
Apr 24, 2025, 4:00 PM EDT - Market closed
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for ACADIA Pharmaceuticals stock have an average target of 23.93, with a low estimate of 19 and a high estimate of 31. The average target predicts an increase of 61.36% from the current stock price of 14.83.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 7 | 7 | 7 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 19 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +88.81% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $20 | Hold | Initiates | $20 | +34.86% | Mar 7, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $28 | Buy | Reiterates | $28 | +88.81% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +82.06% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +88.81% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
1.08B
from 957.80M
Increased by 13.07%
Revenue Next Year
1.19B
from 1.08B
Increased by 9.88%
EPS This Year
0.66
from 1.36
Decreased by -51.34%
EPS Next Year
1.00
from 0.66
Increased by 51.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | 1.6B | ||
| Avg | 1.1B | 1.2B | 1.3B | ||
| Low | 994.3M | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.8% | 30.7% | 36.2% | ||
| Avg | 13.1% | 9.9% | 10.8% | ||
| Low | 3.8% | -1.3% | -3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.40 | 1.97 | 2.50 | ||
| Avg | 0.66 | 1.00 | 1.45 | ||
| Low | 0.08 | 0.33 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7% | 198.3% | 149.3% | ||
| Avg | -51.3% | 51.5% | 44.7% | ||
| Low | -94.2% | -49.7% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.